• Xiao-Dong Wen, Chong-Zhi Wang, Chunhao Yu, Zhiyu Zhang, Tyler Calway, Yunwei Wang, Ping Li, and Chun-Su Yuan.
• State Key Laboratory of Natural Medicines, China Pharmaceutical University Nanjing 210009, China , Tang Center for Herbal Medicine Research, University of Chicago, Chicago, IL 60637, USA , Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA.
• Am. J. Chin. Med. 2013 Jan 1; 41 (5): 1097-108.

AbstractInflammatory bowel disease increases the risks of human colorectal cancer. In this study, the effects of Salvia miltiorrhiza extract (SME) on chemically-induced colitis in a mouse model were evaluated. Chemical composition of SME was determined by HPLC analysis. A/J mice received a single injection of AOM 7.5 mg/kg. After one week, these mice received 2.5% DSS for eight days, or DSS plus SME (25 or 50 mg/kg). DSS-induced colitis was scored with the disease activity index (DAI). Body weight and colon length were also measured. The severity of inflammatory lesions was further evaluated by colon tissue histological assessment. HPLC assay showed that the major constituents in the tested SME were danshensu, protocatechuic aldehyde, salvianolic acid D, and salvianolic acid B. In the model group, the DAI score reached its highest level on Day 8, while the SME group on both doses showed a significantly reduced DAI score (both p < 0.01). As an objective index of the severity of inflammation, colon length was significantly shorter in the model group than the vehicle group. Treatment with 25 and 50 mg/kg of SME inhibited the shortening of colon in a dose-related manner (p < 0.05 and p < 0.01, respectively). SME groups also significantly reduced weight reduction (p < 0.05). Colitis histological data supported the pharmacological observations. Thus, Salvia miltiorrhiza could be a promising candidate in preventing and treating colitis and in reducing the risks of inflammation-associated colorectal cancer.

29 keywords...

hide…